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AIM OF THE STUDY 
                              
 To grade bone marrow fibrosis using reticulin stain and to correlate bone 
marrow microvesseldensity[neoangiogenesis] with reticulin fibrosis and 
splenomegaly. 
  
OBJECTIVE 
 
1. To grade Bone Marrow Fibrosis using Gomori’s silver stain[Reticulin 
Stain]. 
2. To grade Bone Marrow Microvessel density in all the cases of Bone 
Marrow fibrosis. 
3. To analyse the neoangiogenesis in bone marrow fibrosis occurring due to 
various causes. 
4. To correlate Bone Marrow Fibrosis with Microvessel Density. 
5. To correlate Bone Marrow Fibrosis and Microvessel Density with 
Splenomegaly. 
 
  
  
INTRODUCTION 
 
 Myelofibrosis is defined as the pathological process     characterized by 
increased deposition of collagen type I and type III  in the Bone marrow 
secondary to release of fibroblast growth factors.   
 Fibroblast growth factors include PDGF,Epidermal growth  
factor,Endothelial growth factor,TGF–beta.These factors are present in the 
alpha–granules of megakaryocytes. 
 Bone marrow fibrosis usually results from increased stimulation of 
fibroblasts secondary to release of tumour necrosis factor alpha , IL1alpha and 
IL–1beta which are produced by bone marrow cells. 
 Fibroplasia is usually associated with increase in blood flow through the 
marrow of Intramedullary hematopoiesis,resulting in extramedullary 
hemopoiesis which frequently affects liver and  spleen. 
 Extramedullary hematopoiesis is associated with poor prognosis.Hence 
studying the correlation of fibroplasia,spleen size and marrow angiogenesis may 
be helpful in predicting disease   outcome and the patients survival.                   
  
                                REVIEW OF LITERATURE 
 
EXAMINATION OF BLOOD ELEMENTS 
              Careful assessment of the blood elements is often the first and most 
important step in assessment of hematologic function and diagnosis. Many 
hematologic diseases are defined by results of blood tests. Examination of well 
prepared blood smears and hematologic parameters often yields very important 
diagnostic information,allowing the investigator to have broad differential 
diagnostic impressions and helping lot in directing additional specific 
tests.Details on Cellular morphology of various cells present in the blood 
including erythrocytes, leucocytes (neutrophils, eosinophils, basophils, 
monocytes, lymphocytes) and thrombocytes and evaluating the variety of 
parameters relating to cellular size and shape also helps in the diagnosis of 
specific haematological disorder.  
 
CELL COUNT AND MORPHOLOGY 
 Cell counts are most important parameters in evaluating the blood. Cell 
counts are usually determined either manually or by using a standard automated 
hematology analyzers. Whether performed by manual means or by using 
automated methodologies, the accuracy and precision of the count depends on 
correct dilution of the blood sample, even distribution of blood cells and precise 
sample measurement. As blood contains very large numbers of cells, sample 
dilution must be done for accurate analysis. The type of diluent is dependent on 
the cell type to be enumerated. Thus, red cell counts require dilution with an 
isotonic medium, whereas in white cell or platelet counts, a diluent that lyses 
the more numerous red cells is often used.  
Manual counts are done using a light microscope after appropriate dilution of 
the sample in a hemocytometer, a specially made counting chamber that 
contains a specific volume. Red cells,leukocytes,and platelets may be counted. 
Due to the inherent imprecision of manual counting and the amount of technical 
time required, most cell counting is now performed by using automated 
analysers.  
  Evaluation of leukocyte differential count using automated analysers 
markedly reduces the time and cost of doing routine examinations as well as 
increasing the accuracy to a CV of 3% to 5% However, automated analyser is 
highly incapable of accurately identifying and classifying all types of white 
blood cells and in particular insensitive to atypical or immature cells. Therefore, 
most of the analyzers will flag the possible abnormal white cell populations, 
indicating the need for examination by a skilled pathologists for morphological 
identification
40
.Despite giving good results automated analysers sometimes may 
show spurious increase or decrease in the cell count which may be inherent to 
disease itself or analyser.This is mainly due to improper calibration of the 
instrument.Hence the values given by automated analysers should always be 
interpreted in context to clinical findings. 
 Studying the cell morphology mainly red blood cells and white blood 
cells plays a major role in establishing the correct diagnosis.Red cells exhibit 
many a number of morphological variation.Red cell morphology evaluation 
helps in diagnosing many pathological disorder especially primary idiopathic 
myelofibrosis. Red cells may acquire various shapes including sickle shape in 
sickle cell disease,acanthocyte in abetalipoproteinemia,burr cells in uremia and 
tear drop cells in primary myelofibrosis. 
 
HEMATOPOIESIS AND BONE MARROW 
           The initial transient hematopoiesis in human  is called as primitive 
hematopoiesis.This gives rise only to red cell precursors and macrophages, but 
not giving rise to lymphocytes or granulocytes.This is eventually replaced by 
definitive hematopoiesis arising from anterior part of  Aorta-Gonad-
Mesonephros system. This ends after the formation of definitive hematopoietic 
cells.Soon after the formation of definitive hematopoietic cells they seed the 
liver,thus making liver an important site of hematopoiesis.Later during  the fetal 
development the hematopoiesis in liver is eventually replaced by bone marrow. 
          Bones consist of two main parts namely outer cortex and inner 
medulla.Cortex which forms the outermost portion of the bone is usually 
compact and stronger .The inner medulla is usually soft and is composed of 
cancellous bone.Bone marrow is either red or yellow containing hematopoietic 
precursor cells or fatty tissue.The marrow cellularity in normal human being is 
largely dependant on age.In the new born and in childrens generally the entire 
cavity of the bone marrow is completely replaced by actively multiplying and 
dividing hematopoietic elements.As the age increases the hematopoietic marrow 
contracts centripetally,being replaced by adipose tissue resulting in reduced  
bone marrow cellularity. 
   
BONE MARROW TOPOGRAPHY 
 Marrow is composed of two niches namely osteoblastic niche and 
vascular niche.Endosteum of mature lamellar bone is lined by 
osteoblast.Osteoblast play a major role in providing growth factors to 
hematopoietic stem cell and in differentiation of hematopoietic 
elements.Vascular niche is constituted by sinusoids.Stromal component of  bone 
marrow provides medium for survival of hematopoietic elements through 
supplying growth factors.Adhesion molecules provides tight interaction 
between hematopoietic cells and stromal component.   
 In the marrow cavity immature cells are usually found in the 
paratrabecular region.Thus immature cells like blast cells are seen in the 
paratrabecular region.As the cells mature they migrate towards the sinusoids 
afterwhich they enter peripheral circulation.Megakaryocytes are generally seen 
around the sinusoids.The change in the normal topography of marrow cells is 
called Abnormal localisation of immature precursors(ALIP) which is 
characteristically seen in myelodysplastic syndrome and  in some 
myeloproliferative neoplasms.   
 
MYELOPROLIFERATIVE NEOPLASMS 
 
 The myeloproliferative neoplasms are a group of diseases which results 
from the proliferation of a clone of myeloid cells that are derived from a 
neoplastic precursor cell.There are many existing evidences saying that even 
when differentiation of cell is predominantly towards the single lineage ,the 
disorder should have arisen from multipotent myeloid stem cell or atleast in 
some cases ,from a  pluripotent stem cell capable of giving rise to cells of both 
myeloid and lymphoid lineages.In chronic myeloproliferative neoplasms 
,maturation of the cells is relatively normal and thus cells retains some 
responsiveness to normal physiological controls.  
           The myeloproliferative neoplasms differ from myelodysplastic syndrome 
in that,during early phase of the disease the hematopoiesis is effective with 
overproduction of cells of atleast one lineage.Dysplastic features either may be 
totally absent or not very prominent.However ,with the progression of the 
disease,hemopoiesis may become more ineffective and dysplastic features may 
appear.  
 
BONE MARROW FIBROSIS 
 The fibroblastic proliferation in marrow is not an intrinsic part of the 
abnormal clonal expansion of hematopoiesis
(1)
.In case of idiopathic 
myelofibrosis in which G-6PD isoenzyme studies (or) chromosome karyotyping 
establish monoclonal growth of hematopoietic cells, marrow fibroblasts contain 
both G-6-PD isoenzymes and do not share the chromosome abnormality
(2)
. This 
suggests that the fibroblasts differentiate from a primordial cell different from 
the hematopoietic stem cell and their proliferation and enhanced collagen 
synthesis is a secondary result of abnormal hematopoiesis. 
     Fibrosis of bone marrow is not unique to primary myelofibrosis but is 
associated with many other malignant disorders including Acute myelofibrosis, 
Acute myeloblastic leukemia, Acute lymphoblastic leukemia, Hairy cell 
leukemia, Hodgkin’s lymphoma, Non Hodgkins lymphoma, Metastatic deposits 
from breast,lung prostate, stomach and Multiple myeloma. It can also occur in 
non-malignant conditions including infectious conditions including 
Tuberculosis and Histoplasmosis, Renal osteodystrophy ,SLE, Scleroderma, 
Radiation exposure,Thorotrast exposure,etc. 
 
                            Various  Causes for Bone Marrow Fibrosis 
 
              Hematologic Disesases 
Nonhematological 
Disorders Myeloid neoplasms 
Lymphoid 
malignancies 
1.Primary idiopathic 
myelofibrosis 
Hodgkin lymphoma Metastatic carcinomas and 
Sarcomas. 
2.Chronic myelogenous 
leukemia 
3.CNL 
Hairy cell leukemia Autoimmune diseases. 
4.Myelodysplastic 
syndrome(MDS) 
5. Acute megakaryocytic 
leukemia 
Non-Hodgkin 
lymphoma  
 
 
 Tuberculosis. 
6.CMML Multiple myeloma   Kala-Azar (leishmania)sis)  
7.CEL  Systemic lupus 
erythematosis. 
8. Mastocytosis  Acute lymphoblastic       
leukemias 
AIDS 
 Renal osteodystrophy 
 
 
  
 
 
  Familial infantile 
myelofibrosis  
     
 
PRIMARY IDIOPATHIC MYELOFIBROSIS 
                          Primary marrow fibrosis is a clonal myeloproliferative 
neoplasm of pluripotent stem cell which is characterised by the proliferation of 
multiple cell lineage along with progressive increase in marrow fibrosis.It is 
characterised by splenomegaly,marrow fibrosis,leucoerythroblastic picture and 
extramedullary hematopoiesis. 
 In the early phase of idiopathic myelofibrosis ,there may be no increase in 
bone marrow reticulin fibrosis.When there is  increase in bone marrow reticulin 
fibrosis ,it is usually accompanied by increase in bone marrow megakaryocytes 
which will be often morphologically abnormal.  
  Bone marrow aspiration study often yields a cell poor tap or a 
hemodilute material.Hence trephine biopsy is always needed to make a definite 
diagnosis.Smears from successful aspirates may show no abnormality,but 
usually there is neutrophilic and megakaryocytic hyperplasia.Megakaryocytes 
are often morphologically abnormal. 
                        MORPHOLOGY IN MYELOFIBROSIS 
 
 
PREFIBROTIC STAGE FIBROTIC STAGE 
PERIPHERAL SMEAR PERIPHERAL SMEAR 
1.No leucoerythroblastosis. 
2.Minimal anisopoikilocytosis. 
3.Few tear drop cells. 
1. Leucoerythroblastosis. 
2.Prominent poikilocytosis. 
3.Many tear drop cells. 
BONE MARROW BONE MARROW 
1.Hypercellular 
2.Trilineage hyperplasia. 
3.Megakaryocytic atypia. 
4.Minimal reticulin fibrosis. 
1.Decreased cellularity. 
2. Dilated marrow sinusoids. 
3.Marked atypia in 
megakaryocytes. 
4.Reticulin/collagen fibrosis. 
 
 
BONE MARROW FIBROSIS IN MYELOPROLIFEATIVE DISORDERS  
 Groopman
(3)
 first hypothesised that growth factors released from  
haematopoietic cells in MMM were capable of stimulating marrow fibroblastic 
proliferation and suggested that megakaryocyte was the primary source of such 
proliferation factors.The role megakaryocytes in the development of fibrosis in 
MMM is further supported by megakaryocytic hyperplasia with dysplasic or 
necrotic megakaryocytes that  characterises this disorder.The supportive 
evidence to this fact also came from the demonstration of increased fibrosis of  
Bone marrow in Gray platelet syndrome an inherited disorder of platelet alpha-
granule 
(4-6)
  and increased fibrosis from the cases of Acute Megakaryocytic 
leukemia. 
          Castro-Malaspina and co-workers
(7)
 subsequently showed that 
megakaryocyte enriched marrow cell homogenates and platelet homogenates 
induced DNA synthesis by human marrow fibroblast.This group also 
hypothesized that ineffective megakaryocytopoiesis in MMM results in 
liberation of excessive amount of growth factors,leading to marrow fibroblast 
expansion and collagen synthesis
(7)
. 
        Platelet derived growth factors(PDGF), TGF-beta and epidermal growth 
factors(EGF), each of which is contained within platelet and megakaryocyte 
alpha-granules,stimulate marrow fibroblastic proliferation
(8-10)
. 
        TGF–beta enhances type I and type III procollagen,fibronectin synthesis by 
marrow fibroblast
(9)
.Kimura and associates
(11)
 showed that myeloproliferative 
disease fibroblasts are more sensitive to human serum mitogens than normal 
marrow fibroblasts. 
        Martyre and collegues
(12,13)
  further examined the possibility that platelet 
alpha-granule constituents may account for marrow fibrosis in MMM. 
        The PDGF content of platelets from MMM patients is decreased, 
indicating that there is leakage (or) release of such growth factors by marrow 
megakaryocyte
(12,13)
. 
        TGF-beta enhances fibronectin and collagen type I,III and IV as well as 
chondroitin or dermatan sulphate and proteoglycan gene expression
(14,15)
. TGF-
beta reduces the production of various collagenase- like enzymes that degrade 
extracellular ground substances and simultaneously also stimulate the formation 
of protease inhibitors
(16)
. 
          Circulating megakaryocyte and platelet express high level of   
b FGF.These findings may suggest that  b FGF also play a crucial role in 
progressive fibrosis
(17,18)
. 
            Thrombocytes store and release the calcium binding protein 
calmodulin
(18,19)
.Extracelular calmodulin is a mitogen for variety of cells 
including fibroblasts
(8,10)
.Urinary calmodulin excretion is significantly increased 
in patients with MMM compared to normal individuals without fibrosis
(19)
. 
 
PROGRESSION OF FIBROSIS IN MMM 
        In Wolf and Nieman’s series, morphological evidence of progression of 
fibrosis was present in 1 of 21 cases in which sequential biopsies were 
obtained.No connection was observed between bone marrow cellularity, fibrosis 
and splenic size
(56)
. 
          In contrast, Lohman and Beckman observed progressive fibrosis in 18 of 
20 patients who did not have maximal myelofibrosis at the of initial 
biopsy
(57)
.Thiele and colleagues presented data to indicate an early prefibrotic 
subtype of MMM with no (or) minimal medullary reticulin and another phase 
with conspicuous fibrosis and osteosclerotic changes of the marrow.Based on a 
careful histomorphometric evaluation of the bone marrow they concluded that 
in a subset of patients there was a progressive fibro-osteosclerotic process 
during the evolution of the disease. 
          Although a steady progression to marrow fibrosis has been demonstrated 
in patients with prefibrotic stage of myelofibrosis
(58,59,60)
 , fibrosis may remain 
static (or) diminish in advanced stage of  myelofibrosis
(61)
. 
           Among all the patients of myelofibrosis 20 to 25% of patients are 
believed to present with the prefibrotic phase of MMM. Most of the patients go 
on to develop marrow fibrosis over a period of  three to four 
years.Morphological abnormalities of megakaryocytes are reported to be 
conspicuous during prefibrotic stages and permit these patients to be 
distinguished from myelodysplasia with fibrosis. The megakaryocytes often 
appears in clusters adjacent to sinuses and trabeculae. 
 
DIAGNOSTIC CRITERIAS FOR MMM 
          Many diagnostic  criterias have been  proposed for the diagnosis of 
primary idiopathic myelofibrosis. 
                                                                                                                                                         
 WORLD HEALTH ORGANISATION-DIAGNOSTIC CRITERIA 
                   Diagnosis requires all 3 major and 2 minor criteria. 
 
 
MAJOR CRITERIA 
1.Presence of megakaryocyte proliferation and atypia, usually accompanied by 
either reticulin and /(or)  collagen fibrosis. 
                                     (or) 
          In the absence of significant reticulin fibrosis,the megakaryocyte changes 
must be accompanied by an increased bone marrow cellularity characterised by 
granulocytic proliferation and often decreased erythropoiesis (ie.prefibrotic 
cellular phase disease). 
 
        2.Not  meeting WHO criteria for polycythemia vera, BCR-ABL +  chronic 
myelogenous leukemia, Myelodysplastic syndrome,or other myeloid neoplasm. 
       3.Demonstration of  JAK 2 V617F or  other clonal marker 
(MPLW515K/L). 
or 
      In the absence of a clonal marker,no evidence that the bone marrow fibrosis 
(or) other changes are secondary to infection,autoimmune disorder or other 
chronic inflammatory condition,hairy cell leukemia (or) other lymphoid 
neoplasm,,metastatic malignancy, (or) toxic chronic myelopathies. 
 
MINOR CRITERIA 
                1.Anaemia. 
             2.Leukoerythroblastic picture. 
             3.Splenomegaly. 
             4.Raised serum lactate dehydrogenase level.                                                                 
 
 
THE COLOGNE CRITERIA FOR DIAGNOSIS AND STAGING OF 
MYELOFIBROSIS 
A.No  preceding or allied other subtype of myeloproliferative disorders or 
MDS. 
 B. Splenomegaly . 
 C. Thrombocytopenia. 
 D.Anemia . 
 E.Leukoerythroblastic blood picture.           
  F.Histopathology : megakaryocytic plus granulocytic   myeloproliferation with  
large, multilobulated nuclei containing megakaryocytes that show abnormal 
clustering and definitive maturation defects and  
        
            1.No reticulin fibrosis 
            2.Slight  reticulin  fibrosis 
            3.Marked increase in reticulin fibers or collagen fibrosis 
            4. Osteosclerosis . 
 Diagnosis and classification of IMF are acceptable if the following 
combinations are present: 
        Stage 1:   A + B + C + F is consistent with a hypercellular   (prefibrotic) 
stage clinically simulating ET. 
        Stage 2:    A + B + C + D + F - early IMF. 
        Stage 3:   A + B + D + F -  manifest IMF. 
        Stage 4:   A + B + D + E + F-  advanced IMF which is complicated                                        
by osteosclerosis.                                                                                       
 
 MARROW  FIBROSIS AND OTHER MYELOPROLIFERATIVE 
DISORDERS 
                    Marrow fibrosis can occur in patients with other myeloproliferative 
disorders, especially Polycythemia vera and CML, and less frequently in 
primary thrombocythemia
(62,63)
. In CML progressive marrow fibrosis usually 
heralds the onset of accelerated disease (or) blast crisis
(64)
. 
 Myelofibrosis in CML occurs in two different patterns,One in which 
patients present with CML and significant marrow fibrosis, second in which the 
myelofibrosis develops late in course of  CML. Usually myelofibrosis in  CML 
occurs late at a mean of  36 months, after the diagnosis of CML. 
 Post polycythemic myeloid  metaplasia occurs  in 5% to 15%  of       
patients with  polycythemia vera. This occurs usually 10 years after the initial 
diagnosis of  polycythemia vera. In such cases previous history of 
erythropoiesis is very important  in the diagnosis of myelofibrosis secondary to 
polycythemia vera. 
 
 
 
 
 
 ACUTE MYELOFIBROSIS 
                 A clinically distinct entity called Acute Myelofibrosis differs from 
MMM in many aspects. Patients clinically present with pancytopenia , fever, 
absence  of significant splenomegaly, absence (or) minimal tear drop  cells in 
blood smear, and  marrow fibrosis
(66)
. Bone marrow in such cases are 
characterised by the appearance of immature myeloid elements, and the blast 
cells frequently megakaryocytic phenotypic properties.Acute myelofibrosis is a 
form of acute megakaryoblastic leukemia.Distinction from MMM is vital, 
because chemotherapy is needed in case of acute myelofibrosis. 
 
  AUTO IMMUNE MYELOFIBROSIS 
               The appearance of autoimmune myelofibrosis is indistinguishable 
from MMM. Auto immune myelofibrosis occurs predominantly in 
female.Pacquette and colleagues reported that 12% of patients who present with 
myelofibrosis might suffer from an underlying autoimmune disorder such as 
SLE. 
  In  addition millarkat and co-workers suggested the existence of an 
entity,primary autoimmune myelofibrosis(AIMF), a distinct entity unrelated to 
other well defined autoimmune disorder.They described eight diagnostic 
criterias including marrow fibrosis (reticulin fibrosis 3(or)4 ), lack of clusters of 
altered megakaryocytes, lack of dysplasia (or) eosinophilia (or) 
basophilia,lymphoid infiltration of marrow, lack of osteosclerosis, absence of 
spleen enlargement/mild splenomegaly,presence of auto antibodies and absence 
of disorders associated with myelofibrosis. 
 
MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME 
         A variant of myelodysplastic syndrome with myelofibrosis has been 
described by  pagliuca and co-workers. These patients frequently present with 
cytopenias and have cellular dysplastic abnormalities indistinguishable from 
those of other patients with  myelodysplasia. Their marrows, however are 
characterised by the presence of marrow fibrosis , and a striking 
megakaryocytic hyperplasia, with a predominance of small hypolobated forms, 
in some cases surrounding fibrosis.  
 
INFECTIONS AND FIBROSIS 
          The two most important infectious diseases which results in bone marrow 
fibrosis are disseminated tuberculosis and Histoplasmosis. Caseating or non-
caseating granulomas observed on bone marrow biopsy suggest the presence of  
these infectious diseases, and should be pursued by culture techniques if 
possible. 
 
 
METASTATIC CARCINOMAS AND FIBROSIS 
 
                Secondary myelofibrosis frequently occurs in patients with metastatic 
carcinoma of stomach,prostate,lung and breast. Successful treatment of  primary 
neoplasms has resulted in the reversal of marrow fibrosis. Demonstration of 
carcinoma cells in the marrow establishes that metastatic carcinoma is the cause 
of marrow fibrosis. Lytic bone lesion with myelofibrosis suggests the presence 
of underlying carcinomas. 
 
HAIRY CELL LEUKEMIA AND MYELOFIBROSIS 
           Many a times, Hairy cell leukemias can be confused with MMM. Many 
patients who had originally been diagnosed as having MMM were shown 
retrospectively to have had hairy cell leukemia.Hairy cell leukemia can present 
as pancytopenia with splenomegaly and is associated with a dry marrow tap. 
The presence of hairy mononuclear cells possessing tartrate-resistant acid 
phosphatase (or)  appropriate  phenotype in the peripheral blood (or)  marrow 
should facilitate the differentiation of MMM from Hairy cell leukemia. 
 
 
 
 
ROLE OF EMPERIOPOIESIS IN MMM 
           Emperiopoiesis is defined as the random entry of hematopoietic cells into 
the cytoplasm of megakaryocytes.There is increased emperiopoiesis of 
neutrophils and eosinophils in MMM leading to liberation of myeloperoxidase- 
positive granules by engulfed neutrophils which resulted in increased 
fibrosis
(20)
. Abnormal p-selectin distribution in megakaryocytes accounted for 
the selective sequestration of granulocytes by megakaryocytes. 
 
 CELL COUNTS AND MORPHOLOGY IN MMM 
  Approximately 10% of patients present with pancytopenia   because of 
severe impairment of hematopoiesis affecting each cell lineage,coupled with 
sequestration in a massively enlarged spleen.Pancytopenia is usually associated 
with  intense marrow fibrosis. 
 The mean platelet count ranges from 175 to 580 x10
9
/litre at the time of 
diagnosis.Individual count can range from 150 to 3215x10
9
/litre.Platelet count 
is elevated in 40% of patients. Moderate thrombocytopenia is found in one third 
of the patients. Giant platelets and abnormal platelet granulation are 
characteristic features of the disease. 
          The total WBC count show mild increase as a result of granulocytosis. 
The mean total blood white cell count was 10 to 14 x 10
9
 per litre. Myelocytes 
and promyelocytes are present in small proportions in most patients, and a low 
proportion of blast cells(0.5-2%) may be found in the blood film. 
Hypersegmentation,hypo-segmentation and abnormal granulation of neutrophils 
may be present. 
 Mean haemoglobin concentration ranges from 9.0 to 12.0grams/dl. 
Anisocytosis and poikilocytosis are constant findings. In all cases tear-drop 
shaped red cells are seen in sufficient number. Nucleated RBC’s may constitute 
around 2% of nucleated cells in the peripheral blood examination. In some 
patients hemolysis may be prominent,due to production of red cell auto 
antibodies. 
 
CD  34
+
 IN PERIPHERAL BLOOD 
        Borosi and co-workers reported that number of circulating CD34
+
 cells 
tend to increase as the disease progresses and there is a greater chance of 
evolution to leukemia with more circulating CD34
+
 cells(>300x10
6
 CD 34
+
  
cells/litre) in peripheral blood. 
ANGIOGENESIS 
  Angiogenesis (or) formation of new blood vessels may be integral to 
solid tumor growth and metastasis
(21)
. Quantification and analysis of degree of 
intra tumoral angiogenesis may furnish some important prognostic information 
in certain solid  tumours
(22-27)
. 
 In Hematological diseases,Bone marrow is the principal site of disease 
activity and a easily accessible tissue for the investigation of angiogenesis.The 
human marrow cavity is usually supplied by a less number of blood vessels.The 
number of these vessels or the marrow neoangiogenesis is increased in various 
haematological disorders including acute lymphoid leukemia
(28)
,acute myeloid 
leukemia
(29)
,Myelodysplastic syndrome
(30)
,Chronic myeloid leukemia
(31)
 and 
plasma cell disorder
(32)
.Furthermore, microvessel density has been correlated 
with unfavourable prognosis in multiple myeloma. 
         Angiogenesis is a important process in the development and progression 
of solid neoplasms and take part in the phenomenon of metastasis.Thus the 
grading of microvessel density provides useful prognostic information in 
haematological neoplasms such as acute leukemia, MDS
(34,35)
and multiple 
myeloma
(36,37)
. 
           Among all the chronic myeloproliferative disorders, angiogenesis is most 
evident in primary myelofibrosis(MMM)
(38,39)
. 
           In a study conducted by E.Boveri et al, patients with primary 
myelofibrosis were found to have significantly higher value of MVD than those 
with polycythemia vera, Essential thrombocytosis and controls. 
           Angiogenesis in the bonemarrow is an important factor in the 
development and progression of IMF.Allogenic stem cell transplant normalizes 
the increased MVD and disease progression in IMF. 
 Tumor angiogenesis is believed to be co-ordinated by a fine balance 
between angiogenic activators and inhibitors. Many molecules have been 
implicated as positive regulators of angiogenesis, such as VEGF and b FGF.A 
recent study has shown that there is increased VEGF  in the circulation of 
patient with IMF
(41)
. 
 Increased expression of bFGF also was detected in circulating 
megakaryocytes from patients with idiopathic myelofibrosis. 
 VEGF and b-FGF are potent angiogenic growth factors. It has  been 
suggested that VEGF,by binding to its receptors can inhibit apoptosis of 
endothelial cells and stimulate endothelial cell migration and 
proliferation
(42)
.bFGF has been shown to induce endothelial cell 
proliferation,migration and tubulogenesis
(43)
.Recent data from(Grunewald et 
al)
(44)
 suggested that the recruited bone marrow derived circulating 
hematopoietic cells can stimulate endothelial cell proliferation and blood vessel 
sprouting through increased VEGF secretion. 
 It is believed that angiogenesis in tumours develops by the phenomenon 
of blood vessel sprouting from already existing vascular structures through 
division of fully differentiated endothelial cells
(45)
. However,recent studies have 
suggested that angiogenesis also could occur through the de novo formation of 
blood vessels by bone marrow derived angioblasts (or) common precursor 
called hemangioblast.
(46,47) 
Gunsilins et al
(46)
 demonstrated that human bone 
marrow derived endothelial progenitor cells can integrate into the endothelial 
cells of blood vessels. 
   Massa et al
(47)
 demonstrated increased endothelial progenitor cells in 
patient with IMF. These results suggest that the recruitment and insitu 
differentiation of bone marrow – derived endothelial progenitor cells also may 
be essential to promote effective neovascularisation. 
       
MICROVESSEL DENSITY GRADING 
 
 QUANTITATIVE MORPHOMETRIC MEASUREMENT OF MVD – 
Niet et al 
             The histologic sections of bone marrow,were stained first 
immunohistochemically for CD34.After staining the sections were examined 
using a light microscope. The entire section was scanned at 100x 
magninification.Microvessels were identified as endothelial cells appearing as a 
single cell or cells clustered in nests either with or without lumen.Vessels with 
thick tunica media,vessels near the periosteum, and sinusoids were excluded. 
             For quantitative analysis of MVD, 2 photographs were taken from the 
central portion of each bone marrow section by an investigator(H.N.)  without 
knowledge of the source of the specimen. The MVD was measured using a 
multipurpose morphometric analysis   system proposed by Weibel. Each 
photograph were coded and shuffled and then examined randomly,with the 
observer performing the analysis unaware of the source of the specimen. 
Random sampling was achieved by using a multipurpose test system that was 
superimposed on each photomicrograph.This system consists of 84 lines/168 
points on a field of 145.5 cm. The presence of microvessels at sample point was 
recorded. The MVD was estimated by counting the points lying over 
microvessels, The final result was expressed as a volume percent of 
microvessels present in the bone marrow using a formula as follows: 
                                               V =Pa/Pc x 100% 
   Pa represents the point number on the microvessel;Pc,the test point number; 
and V , the volume of the  microvessels. 
 
 MEASUREMENT OF MICROVESSEL DENSITY – Mesa et al 
 Three separate methods were used to estimate MVD. 
  METHOD I 
                      1.Visual scanning of stained slides at all the    
                       magnification(100X,400X). 
                      2.Semiquantitative grading for CD34 staining. 
                      3.Accuracy of the method is ensured by review of the  
                       slides by two authors. 
                      4.To ensure vessel specific staining morphologic analysis  
    
                     was done. 
METHOD II 
 
                       1.Scanning of slide at 100X. 
                       2.Three areas with more number of blood vessels(hot spot)   
                         selected. 
                       3.Absolute number of vessels was determined at 400X. 
                       4.Average of three separate visual counts devoid of larger  
                         vessels and sinusoids was taken as MVD. 
 
 
METHOD III 
 
              In the third and final method, bone marrow MVD was estimated by 
using computerized image analysis. The 3 hot spots used for the visual count 
were quantified by computer-based image analysis.A PC- compatible computer 
running the image analysis software was used for analysis of digitally captured 
images.By using computerized pixel counting, microvessel surface area was 
calculated and expressed as the percentage of a bone marrow hot spot occupied 
by CD 34 staining.An optimized microvessel surface area was then determined 
by removing the area occupied by fat and expressing the result as a percentage 
of cellular area occupied by CD34 staining.     
 
EXTRA MEDULLARY HEMATOPOIESIS 
           Spleen is an important site of haematopoiesis in utero and retains its 
ability to reactivate this process after birth.This can occur as compensatory 
erythroblastic hyperplasia in anaemias such as haemolytic anaemia,vitamin-B 
deficiency anaemia and thalassemia or as a more generalised haemopoiesis 
often seen in myelofibrosis or other malignant disorders in the bone marrow. 
       Many of the peripheral blood abnormalities associated with IMF may be 
attributed to the extramedullary hematopoiesis.Extramedullary hematopoiesis 
had previously been attributed to the reactivation of  quiescent hematopoietic 
stem cells, which are retained at sites of embryonic hematopoiesis,especially in 
the spleen
(48)
. 
         This hypothesis has been questioned because of the observation that  
spleen,a prominent site of fetal hematopoiesis in humans and by the observation 
that extramedullary  hematopoiesis occurs in wide variety of sites that cannot be 
accounted by this hypothesis
(49-51)
. 
          In IMF, after the CD34+ cells (stem cells)exit from the marrow due to 
their abnormal trafficking patterns,they are filtered by spleen.
(52) 
Ultimately 
there is an unequal distribution of CD34 cells with two fold greater number 
being present in the spleen.The myeloid metaplasia of the spleen is 
characterised by disturbance of splenic architecture with increased proliferation 
of megakaryocytes and their progenitor cells
(52)
  resulting in extramedullary 
hematopoiesis and splenomegaly. 
           In general primitive cells which escape from bone marrow are filtered by 
the spleen and destroyed.If number of such primitive cells exceeds the capacity 
of spleen,these cells are believed to be worked into the peripheral blood, leading 
to clinical picture of eucoerythroblastosis
(53-55)
. 
           Splenic size can be assessed by clinical examination and through 
radiological imaging techniques.The weight of normal spleen ranges from 150-
250g.Considerable variation occurs in splenic weight between normal 
individuals and at various ages in the same individual.At puberty it weighs 200-
300g but it starts decreasing after the age of 65 years to 100 to 150g (or) less.In 
the adult its length is 8-13cm,width is 4.5-7.0cm,surface area 45-80cm
2
 and 
volume less than 275cm
3
. 
             In the adult an enlarged spleen is palpable when the length of the spleen 
exceeds 14cm.However measurement of spleen size by physical examination of 
the abdomen is  highly unreliable, as minor enlargement of spleen is often 
notdetected by palpation and even a grossly enlarged spleen may be missed in 
an obese person. 
             As increase in spleen size is associated with increase in bone marrow 
fibrosis and worse prognosis, it is important to obtain reliable information by 
radiology through ultrasonic imaging,MRI and CT. 
 
 RADIOGRAPHIC EXAMINATION AND MARROW FIBROSIS 
  On radiographic examination, characteristic features of MMM are 
diffuse increase in bone marrow density and increased prominence of the bony 
trabeculae.This increased bone density may be patchy and can produce a 
mottled appearance. 
 
Kaplan and colleagues reported that marrow pattern in the proximal 
femur of MMM patients correlated with the clinical severity of the disease and 
that MRI of the proximal femur might be useful in staging and evaluating the 
progression of the disease process. 
  
                                    MATERIALS  AND  METHODS 
STUDY DESIGN 
                    Prospective study. 
STUDY PLACE 
                     Coimbatore Medical College Hospital. 
STUDY PERIOD 
                     August 2011- July 2012. 
SAMPLE SIZE 
                  25 Cases. 
INCLUSION CRITERIA 
                  Newly diagnosed Bone marrow fibrosis of various etiology in 
patients of all age groups and both sexes admitted to Coimbatore medical 
college hospital. 
EXCLUSION CRITERIA 
1. Already diagnosed patients of bone marrow fibrosis on treatment. 
2. Patients with splenomegaly of causes other than bone marrow fibrosis 
including infections,storage disorders and diseases like 
amyloidosis,idiopathic splenomegaly. 
 
                                           
 
                                        
 METHODOLOGY 
 Among all the bone marrow trephine biopsy specimens received in the 
department of pathology,Coimbatore medical college hospital during the study 
period, 25cases which showed bone marrow fibrosis in routine hematoxylin and 
eosin stain were selected based upon inclusion and exclusion criteria. 
 A proforma was used to register various informations about the patients 
including name,age,sex and clinical profiles including presenting 
symptoms,past history,treatment history as described in annexure -1.Results of 
all the available investigations were obtained from various medical records and 
case sheet. 
 Hematological Profiles including hemoglobin,total leucocyte count and 
platelet count were studied using  automatic analyser sysmex KX-21. The 
results obtained were recorded and were used to correlate with the findings of 
bone marrow trephine biopsy. 
 Morphological abnormalities of red blood cells,white blood cells and 
platelets were studied using peripheral smears stained with leishman stain. 
Some cases which were accompanied by bone marrow aspiration slides were 
also studied after staining with leishman stain.Bone marrow aspirates were used 
to study the following 
                                    1.Cellularity.                   
                                    2.Myeloid:Erythroid ratio. 
                                    3.Myelopoiesis.                
                                    4.Erythropoiesis. 
                                    5.Megakaryocytes.         
                                    6.Presence of abnormal cells including dysplastic 
erythroblasts, micromegakaryocytes, Agranular/hypogranular myeloid 
precursors, lymphoma cells and cells of metastatic carcinomatous deposit. 
                                     7.Parasites. 
 
                                   BONE MARROW STAINING 
 Bone marrow sections were cut at a thickness of 4microns from paraffin 
embedded blocks after fixation and decalcification of bone marrow trephine 
biopsy specimens.Routine hematoxylin and eosin staining was done. 
                    Fixative: 10% neutral buffered formalin. 
                    Decalcifying agent: 5-10%nitric acid(6%in our institution). 
 
PROCEDURE  
1. The slides were kept in Xylene for 15minutes. 
2. Slides washed in graded alchohol. 
3. Slides were washed in water for 5minutes. 
4. Slides stained in hematoxylin for 5minutes. 
5. Slides were washed in water for 5minutes. 
6. Differentiated in 1%acid alchohol(2 dips). 
7. Washed in water for 2minutes. 
8. Dipped in Lithium carbonate (twice) for blueing. 
9. Washed in water for 10minutes. 
10. Dipped in 80% alchohol. 
11. Stained with eosin for 5minutes. 
12. Dehydrated in graded alchohol (80%,90% and then in absolute 
alchohol). 
13. Cleared in xylene and mounted in D.P.X. 
 
BONE MARROW TREPHINE BIOPSY EXAMINATION 
  A Systematic examination of bone marrow trephine biopsy specimens 
was performed and the following details were obtained. 
                               1.Architecture. 
                               2.Cellularity. 
                               3.Presence of dysplastic megakaryocytes. 
                               4.Megakaryocytic clumping(clustering). 
                               5.Fibrosis. 
                               6.Osteosclerosis. 
                               7.Caseation necrosis. 
                               8.Granulomas. 
                               9.Fungal colonies. 
                              10.Lymphomatous infiltration. 
                              11.Metastaic deposit.    
                           
RETICULIN STAIN 
 Reticulin stainining was done after cutting the sections at 4microns 
thickness from paraffin embedded blocks. 
 
METAL  IMPREGNATION TECHNIQUE AS A CHOICE 
                          Techniques for the demonstration of reticular fibres may be 
divided into those using dyes as means of staining and metal impregnation 
methods.Dye techniques for reticulin demonstration cannot be considered 
completely reliable,the density of stain being insufficient to resolve the fine 
fibres.Staining techniques cannot readily differentiate between collagen and 
reticulin fibres. 
 
PROCEDURE 
1. Sections were Deparaffinized and brought to water. 
2. Sections treated with 1%potassium permanganate                           
solution for 1minute. 
3. Rinsed in tap water. 
4. Bleached in 2%potassium metabisulfate solution for                           
1minute,then rinse in  tap water. 
5. Sensitized with ferric ammonium sulfate for 1minute                           
and washed in distilled water. 
6. Impregnated in silver solution for 1minute. 
7. Washed in distilled water several times. 
8. Reduced in 20%formalin solution for 3minutes and then rinsed in tap 
water. 
9. Toned in 0.2%gold chloride for 10minutes.Rinsed in                            
tap water. 
10. Treated with 2% potassium metabisulfite solution for 1minute.Rinsed 
in tap water. 
11. Fixed in 2% sodium thiosulfate solution for 1minute.Rinsed in tap 
water. 
12. Dried in air. 
13. Cleared in Xylene. 
14. Mounted in D.P.X. 
 
INTERPRETATION AND GRADING OF RETICULIN FIBROSIS 
 The stained slides were examined and graded using modified 
Bauermeister scale. They were given the score of 0-4. 
Grade0: No reticulin fibres. 
Grade1:Occassional fine individual fibres and foci of a fine fibre network. 
Grade2:Fine fibre network throughout most of the section.No coarse fibres 
seen. 
Grade3:Diffuse fibre network with scattered thick coarse fibres but no mature 
collagen. 
Grade4:Diffuse often coarse fibre network with areas of 
collagenisation(positive trichrome staining). 
 
            
 
 
 
 
 
 
 
 
 TUMOUR ANGIOGENESIS AND IMMUNOCHEMISTRY 
SECTION CUTTING 
                          The sections were cut at 4microns thickness from paraffin 
embedded blocks.Section cutting was followed by dewaxing (Incubating 
sections at 58*c overnight). 
ANTIGEN RETRIEVAL 
                        Many methods have been used for antigen retrieval including 
pressure cooker method,microwave retrieval,water bath,autoclave and 
proteolytic enzyme digestion.In our institution we used microwave antigen 
retrieval method.(Heat mediated antigen retrieval technique). 
BUFFER 
         Citrate buffer(0.01M) at pH of 6. 
IMMUNOHISTOCHEMISTRY  TECHNIQUE 
           Two step indirect method. 
CD34 AS A CHOICE OF ANTIBODY 
 Initially during the study period many antibodies including CD31,Factor 
VIII,along with CD34 were tried.Results obtained using these antibodies were 
studied and compared among themselves.The results showed that the staining 
using CD31 and FactorVIII were less intense(weakly positive).Also in case of 
antibodies other than CD34 ,staining of primitive cells and blast cells were more 
in number making the interpretation difficult.Hence the antibody (CD34 )which 
gave strong positivity was used as antibody of choice. 
PROCEDURE – IMMUNOHISTOCHEMISTRY 
                             1.Sections are cut at 4microns.Incubate at  
                             58
*
c overnight. 
                             2.Washed in xylene for 30minutes. 
                             3.Washed in absolute alchohol – 2minutes x 2changes. 
                             4.Washed in tap water for 10minutes. 
                             5.Rinsed in distilled water for 5minutes. 
                             6.Kept in microwave : Medium-10minutes;  
                               High-10minutes. 
                             7.Cooled to room temperature- 20minutes. 
                             8. Rinsed in distilled water for 5minutes. 
                             9.Washed in TBS-5minutes x 2changes. 
                            10.Kept in peroxide block for 10minutes. 
                            12.Kept in power block for 10minutes. 
                            13.Drained and covered in with primary antibody  
                               for one hour.                                 
                            14.Washed in TBS-5minutes x 2changes. 
                            15.Kept in superenhancer for 30minutes.                             
                            14.Washed in TBS-5minutes x 2changes. 
                            17.Treated with S.S label and poly HRP for 30minutes. 
                            18.Washed in TBS-5minutes x 2changes. 
                            19.Treated with DAB and substrate buffer for  
                             5-8minutes. 
                            20.Washed in TBS-5minutes x 2changes. 
                            21.Kept in tap water for 5minutes. 
                            22.Kept in hematoxylin for 30seconds-2minutes. 
                            23.Kept in tap water for 5minutes. 
                            24.Dried in air. 
                            25.Cleared in Xylene.Mounted in D.P.X .    
           
GRADING OF MICROVESSEL DENSITY 
  The slides which were stained for CD34 were graded for microvessel 
density(neoangiogenesis).The grading was done using visual microvessel 
density grading system which was introduced by Weidner et al in solid tumours. 
 
PROCEDURE 
 Each of the study slide was first scanned at 100x magnification.Three 
areas with abundant microvessels were selected and defined as hot spots.The 
number of microvessels in each of these hot spots was then determined at 400x 
magnification.The final MVD number [microvessels per high power(400x) 
field] was assigned by taking the average of the three separate visual 
counts.During the process of grading MVD,large vessels and vessels in the 
periosteum or bone and open sinusoids were excluded.Areas of staining with no 
discrete breaks were counted as single vessel and presence of lumen was not 
required. 
The results obtained were graded as follows by comparing with age matched 
controls.After grading,the results were compared among themselves and 
correlated with bone marrow fibrosis(Reticulin fibrosis) and splenomegaly. 
           MVG 1:Slightly increased. 
           MVG 2:Easy to find and definitely increased from normal. 
           MVG 3:Abundant vessels. 
           MVG 4:Markedly increased. 
SPLEEN SIZE 
 Spleen size of the cases were obtained using ultrasonographic 
examination and were divided into three categories as mild,moderate and 
severe.The results were correlated with mean vascular density(MVD) and 
marrow reticulin fibrosis.  
      
                                 OBSERVATION AND RESULTS 
            Total of 25cases were studied.Among 25cases,8cases showed features of 
primary myelofibrosis and remaining 17cases were the cases of secondary 
myelofibrosis. 
TABLE.1 
                                                       
             Among 25 cases studied totally most of the cases (68%) are the cases of 
secondary myelofibrosis.Ratio of primary myelofibrosis: secondary 
myelofibrosis-1:2.This indicates that secondary myelofibrosis is relatively more 
common than primary myelofibrosis.  
  
TOTAL NUMBER OF 
CASES 
PRIMARY 
MYELOFIBROSIS 
SECONDARY 
MYELOFIBROSIS 
                     25                      8               17 
PERCENTAGE(%)                     32%               68% 
                                                  
CHART – 1 
 
 
               The above chart comparison clearly indicates that secondary 
myelofibrosis is more common than primary idiopathic myelofibrosis. 
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                                                 TABLE.2 
    
TOTAL CASES MALES FEMALES 
25 13 12 
PERCENTAGE(%) 52% 48% 
 
                    52% of the total case load was contributed by males.This shows 
that there is slight degree of male preponderance. 
CHART – 2 
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TABLE.3 
 
 
                                                             
 
         The study included totally eight cases of primary myelofibrosis.In the 
eight cases studied 75% of the cases were males with male to female ratio of 
3:1.  
CHART – 3 
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    TOTAL CASES MALES FEMALES 
               8       6         2 
PERCENTAGE(%)      75%        25% 
SEX DISTRIBUTION AMONG SECONDARY MYELOFIBROSIS 
 
TABLE.4 
 
 
 
                                                                  
 
 Maximum number of patients among secondary myelofibrosis were 
females accounting for 58.82%.This is in contrast to primary myelofibrosis 
which showed male preponderance. 
                                            CHART – 4 
 
         
41.18%
58.82%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
MALES FEMALES
   TOTAL CASES MALES FEMALES 
                17      7        10 
PERCENTAGE(%)  41.18%      58.82% 
AGE AND SEX DISTRIBUTION AMONG ALL THE CASES 
TABLE.5 
AGE 
(YEARS) 
CASES MALES FEMALES 
TOTAL 
(%) 
MALE 
(%) 
FEMALE 
(%) 
       10-20     2      2        O     8%     100% 0% 
       21-40     4      0         4    16%       0% 100% 
       41-60    13      7         6    52%    53.85% 6.15% 
       61-80     6      4         2    24%    66.67% 33.33% 
 
 Age distribution studied among all the cases showed that there were two 
cases below 20years.Both of the cases were males with one case being case of 
primary myelofibrosis and other being secondary myelofibrosis.All the cases 
between 21-40 years were females. The maximum number of cases lie between 
41years and 60years. 
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TABLE.6 
                                    
                                   
 
  
 
 
 
 There were no cases between 21years and 40years.There was one case 
below 20years.The maximum number of cases were between 41years and 
60years.       
 
CHART – 6 
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        10-20                1            12.5 
        21-40                0               0 
        41-60                5            62.5 
        61-80                2              25 
             PANCYTOPENIA AND PRIMARY MYELOFIBROSIS 
 
TABLE.7 
            
 Six cases(75%) among the eight cases studied had pancytopenia. 
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TOTAL CASES PANCYTOPENIA CYTOPENIA(TWO 
SERIES) 
               8                6               2 
PERCENTAGE(%)               75%              25% 
PRIMARY MYELOFIBROSIS AND HEMOGLOBIN LEVEL 
 
TABLE.8 
 
   All the patients of primary myelofibrosis had anaemia.75% of patients had 
their hemoglobin between 4.1grams and 6.0grams.No patients had their 
hemoglobin below 4.0grams. 
CHART – 8 
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                   2-4                  0           0 
                  4.1-6                  6          75 
                  6.1-8                  1         12.5 
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PRIMARY MYELOFIBROSIS AND PLATELET COUNT 
TABLE.9 
 
 All the cases had thrombocytopenia.Most of the patients (62.5%) had 
only mild thrombocytopenia.No patients had platelet count below 
20,000cells/mm
3
and hence none of them presented with signs and symptoms of 
bleeding. 
CHART - 9 
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           20000-40000                  1         12.5 
           41000-60000                  2           25 
           61000-80000                  3          37.5 
           81000-100000                  2           25 
DISTRIBUTION OF CASES AMONG SECONDARY    
MYELOFIBROSIS 
                                                     TABLE.10 
 
 
 
 
 
 
 Among secondary myelofibrosis most number of cases(64.71%) were due 
to haematological malignancies including leukemias and lymphomas.Non 
haematological malignancies mainly metastatic carcinomatous deposit accounts 
for 11.76%.  
Chart – 10 
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PERIPHERAL SMEAR AND PRIMARY MYELOFIBROSIS 
TABLE.11 
                                                              
  
 Peripheral smear examination showed anisopoikilocytosis in most of the 
cases and it was found to be constant finding in 87.5% of the cases.Tear drop 
cells which was considered to be pathognomonic feature of idiopathic 
myelofibrosis was found in six (75%) cases.Neutropenia was seen in 50% of the 
cases.None of the cases had increase in the granulocyte count.   
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PANCYTOPENIA ANISOPOIKILOCYTOSIS TEAR DROP CELLS GIANT PLATELETS NEUTROPENIA
              FINDINGS        NUMBER OF     
            CASES 
PERCENTAGE 
      PANCYTOPENIA                   6          75% 
ANISOPOIKILOCYTOSIS                   7         87.5% 
     TEAR DROP CELLS                   6          75% 
     GIANT PLATELETS                   2          25% 
         NEUTROPENIA                   4          50% 
 ANAEMIA DISTRIBUTION AMONG SECONDARY MYELOFIBROSIS 
TABLE.12 
 
 Among the cases of secondary myelofibrosis 52.94% of cases had 
anaemia.All the cases had normocytic normochromic anaemia. 
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TOTAL 
CASES 
ANAEMIA 
MOST COMMON 
TYPE OF               
ANEAMIA 
PERCENTAGE 
17 9 
NORMOCYTIC 
NORMOCHROMIC 
52.94% 
BONE MARROW MORPHOLOGY AND PRIMARY MYELOFIBROSIS 
 
TABLE.13 
  
 
 Among eight cases studied 5 patients showed hypercellular marrow and 3 
patients showed hypocellular marrow.In the patients of hypercellular marrow 
62.5% showed dysplastic megakaryocytes and 37.5% of patients showed 
megakaryocytic clustering.  
 
  
 
 
 
 
 
BONE MARROW 
FEATURES 
NUMBER OF 
CASES 
PERCENTAGE 
  HYPERCELLULAR  
          MARROW 
5 62.5% 
    HYPOCELLULAR  
          MARROW 
3 37.5% 
         DYSPLASTIC 
MEGAKARYOCYTES 
5 62.5% 
MEGAKARYOCYTE  
         CLUSTERING 
3 37.5% 
  INTRASINUSOIDAL  
    HEMATOPOIESIS 
2 25% 
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Most of the cases showed bone marrow hypercellularity with many of them 
showing abnormal shaped megakaryocytes. 
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RETICULIN FIBROSIS  AND GRADING IN PRIMARY 
MYELOFIBROSIS 
TABLE.14 
GRADE OF 
RETICULIN 
FIBROSIS 
 
NUMBER OF 
CASES 
 
PERCENTAGE 
GRADE-1 2 25% 
GRADE-2 3 37.5% 
GRADE-3 3 37.5% 
GRADE-4 0 0% 
 
 Reticulin fibrosis was evident in all the cases with 37.5% of cases 
showing grade 2 fibrosis.None of the cases showed collagen fibrosis and 
osteosclerosis. 
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RETICULIN FIBROSIS AND SECONDARY MYELOFIBROSIS 
TABLE.15 
 
 
 
 
             
 
 Most of the cases among secondary myelofibrosis showed grade1 
fibrosis.They constitute for 64.70% .Only one case showed grade3 fibrosis.  
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RETICULIN 
FIBROSIS 
CASES PERCENTAGE 
  GRADE-1    11        64.70% 
  GRADE-2     5        29.41% 
  GRADE-3     1         5.89% 
  GRADE-4     0           0% 
SPLENOMEGALY AND PRIMARY MYELOFIBROSIS 
TABLE.16 
                                                           
 
 
 
 
 Splenomegaly was found in all the case.Among the cases studied 
3cases(37.5%) had massive splenomegaly.  
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SPLENOMEGALY CASES PERCENTAGE 
MILD 2 25% 
MODERATE 3 37.5% 
MASSIVE 3 37.5% 
PRESENTING COMPLAINTS AND MYELOFIBROSIS 
 
TABLE.17 
PRESENTING 
COMPLAINTS 
NUMBER OF       
CASES 
PERCENTAGE 
 PALLOR           5        62.5% 
 ABDOMONAL PAIN           1        12.5% 
 FATIGUE           1        12.5% 
ASYMPTOMATIC           1        12.5% 
 
 Idiopathic myelofibrosis presents with wide range of symptoms and 
signs.Some of the patients are asymptomatic.In this case study 62.5% of 
patients had pallor.One patient had abdominal pain as a result of 
splenomegaly.One of the patient presented with no symptoms.                     
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Most of the cases presented with the clinical features of anaemia. 
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CORRELATION OF MVD,RETICULIN FIBROSIS AND 
SPLENOMEGALY 
TABLE.18 
S. 
NO 
AGE SEX MARROW 
CELLULARITY 
FIBROSIS SPLENOMEGALY MVD 
1 17yrs M HYPERCELLULAR GRADE-2       MASSIVE MVD-3 
2 72yrs M HYPERCELLULAR GRADE-2     MODERATE MVD-2 
3 56yrs M HYPERCELLULAR GRADE-3     MODERATE MVD-1 
4 52yrs F HYPERCELLULAR GRADE-2        MASSIVE MVD-2 
5 65yrs M HYPERCELLULAR GRADE-1        MASSIVE MVD-1 
6 58yrs F HYPOCELLULAR GRADE-3            MILD  MVD-1 
7 51yrs M HYPOCELLULAR GRADE-1     MODERATE MVD-1 
8 60yrs M HYPOCELLULAR GRADE-3            MILD MVD-1 
 
             
 Increase in the cellularity is associated with increase in mean vascular 
density.With increase in the degree of fibrosis the cellularity tends to 
decrease.Thus there exists inverse relationship between cellularity and 
fibrosis.There exists no relationship between reticulin fibrosis and 
splenomegaly.  
 
 
 
 
 
                           
                              
                             Fig.1.Smear showing mild anisopoikilocytosis with tear drop cells (1000X) 
 
                                    
                                                     Fig.2.Smear showing giant platelet (1000X) 
                                              
                              
                         Fig.3.A Case of aplastic anaemia showing hypoplastic marrow (100X) 
 
                                                 
                                   
                                           
                                     Fig.4.Bone marrow biopsy showing hypocellular marrow (400X) 
                  
                                    
                         Fig.5.A case of primary myelofibrosis showing hypercellular marrow (100X) 
 
 
                                         
                                     Fig.6.Hypercellular marrow with trilineage hyperplasia (100X) 
 
                                
                                 Fig.7. Megakaryocytic clustering in a case of  myelofibrosis (400X) 
 
 
 
                                  
                                           Fig.8.A megakaryocyte with abnormal lobation (400x) 
                                  
                                     
                                                   Fig.9.Intrasinusoidal megakaryopoiesis (400X) 
 
 
 
                                   
               Fig.10.Intrasinusoidal hematopoiesis in a case of extramedullary hematopoiesis (400X) 
  
                                   
                              Fig.11.Extramedullary hematopoiesis in spleen showing a megakaryocyte in    
                               the centre (100X) 
 
                                   
                         Fig.12.Cluster of blast like cells in a splenic extramedullary hematopoiesis (400X) 
                                                                 
                        
                  Fig.13.Early cellular phase of myelofibrosis showing proliferating fibroblasts (400X) 
 
                                                           
                           
                             Fig.14.An entrapped megakaryocyte is seen within coarse fibrosis (400X) 
                                       
                                  Fig.15.A case of CLL showing nodular aggregates of monotonous small  
                                  lymphoid cells (100X) 
 
 
                                       
                                                     Fig.16.A case of CLL  with areas  of fibrosis (400X) 
                                       
                          
                         Fig.17.Epithelioid cell granuloma in a case of disseminated tuberculosis (100X) 
 
 
                                
                                 Fig.18.Epithelioid cells with abundant pale eosinophilic cytoplasm (400X) 
                                            
                               
                      Fig.19.A case of multiple myeloma with sheet of plasma cells.Few binucleate forms   
                      are seen (400X) 
 
                                                       
                         
            Fig.20.A case of SCC (Tonsil) showing radiation induced secondary myelofibrosis (100X) 
                           
                                                          Fig.21.Grade 1 reticulin fibrosis (100X) 
 
                                           
                               
                                                            Fig.22.Fine scattered reticulin fibres (400X) 
                         
                                                             Fig.23.Grade 2 reticulin fibrosis (100X) 
                                                                 
                                     
                               
                                                Fig.24.Fine reticulin fibres with intersection (100X) 
                               
                       
                                                        Fig.25.Grade3 reticulin fibrosis (100X) 
 
                                                              
                               
                                                            Fig.26.Coarse reticulin fibres (400X) 
                                         
                              
                                                 Fig.27.No increase in mean vascular density (400X) 
 
 
 
                                       
                                                           Fig.28.Mean vascular density-Grade1 (400X) 
                                  
                    
                                                  Fig.29.Mean vascular density-Grade2 (400X) 
 
 
                     
                                                  Fig.30.Mean vascular density-Grade3 (400X) 
 DISCUSSION 
          Idiopathic myelofibrosis is a clonal myeloproliferative neoplasm in which 
the proliferation of multiple cell lineages is accompanied by  progressive bone 
marrow fibrosis. 
 
AGE AND SEX DISTRIBUTION 
  According to Barosi.G et al and ozen.s et al idiopathic myelofibrosis 
characteristically occurs after 50 years of age and the mean age at diagnosis is 
65years. In this study most of cases of primary myelofibrosis were over 50years 
and the mean age group at diagnosis was 54. This is comparable with other 
studies.  
 According to Cervantes et al (1998) myelofibrosis can occur from the 
neonatal period to the ninth decade of life. In this study lowest age group 
affected was 17years and highest age group was 72 years. 
  According to okamura.T et al (2001) myelofibrosis, in adults occurs with 
about equal frequency in men and women. In this study male to female ratio is 
3:1(male preponderance). This may be probably due to low number of cases 
involved in the study. 
  In addition to this in this study ratio of primary and secondary  
myelofibrosis is found to be 1:2(1:2.125) which indicates that secondary 
myelofibrosis is more common than primary.Male to female ratio in secondary 
myelofibrosis,according to this study is 1:1.4 (with slight female 
preponderance). 
  SYMPTOMS AND CLINICAL FEATURES 
  According to Varki et al 71% of the cases of myelofibrosis present with 
the complaints of fatiguability and 21% cases presents with no symptoms 
(asymptomatic). 
 According to Silverstein et al 60% of patients present with pallor. From 
above mentioned studies it is clear that maximum percentage of cases present 
with clinical symptoms of anaemia. In this study 75% of cases presented with 
clinical symptoms and signs related to anaemia. 
HEMATOLOGICAL PROFILE AND CELL MORPHOLOGY 
 According to Tefferi A et al, 60% of the cases have their haemoglobin 
level dropped below 10g /dl. In this study, all the cases of primary 
myelofibrosis (100%) had their haemoglobin level below 10gm%. However, 
only 53% of cases of among secondary myelofibrosis had their Hb% below 
10gm/dl. Although all the cases of primary myelofibrosis presented had their 
haemoglobin percentage below 10g/dl,it is often difficult to estimate the degree 
of anaemia using haemoglobin (or) Hematocrit, as most of the individuals with 
increased spleen size have expanded plasma volume resulting in anaemia. 
  According to Barosi et al
  
the most common type of anaemia among the 
patients of idiopathic myelofibrosis is normocytic normochromic anaemia. Most 
common type of anaemia among the cases in this study is found to be 
normochromic and normocytic with  dacryocytes in 75% of the patients of 
primary myelofibrosis and anisopoikilocytosis in 87.5% of the patients.None of 
the patients presented with haemolytic anaemia. This shows that none of the 
cases had hypersplenism (or) anti-erythrocyte autoantibodies. 
           According to Tefferi et al 13% to 25% of patients present with 
leucopenia and leucocytosis occurs in one third of the patients. In this study 6 
out of 8 patients presented with leucopenia while two of the patients had normal 
total leukocyte count. No patient presented with leucocytosis. This may be 
probably due to the fact that, most of the patients presenting in late phase of 
disease. 
 In Mayo clinic series of 169 patients, platelet count of less than 
1,00,000/mm
3 
was found in 31% of the patients. In this study all the 
patients(100%) presented with thrombocytopenia. Giant platelets were observed 
in 2 out of 8 cases. 62.5%(5 out of 8 cases) had their platelet count between  
60,000/mm
3
 and 1,00,000/mm
3
. 
 
FIBROSIS  IN DISORDERS OTHER THAN PRIMARY 
MYELOFIBROSIS 
            According to Najeany et al fibrosis can accompany various disorder like 
polycythemia vera and chronic myeloid leukemia.In this case study we had 
fibrosis accompanying 2 cases of CML (2 out of 17).It constituted for 11% of 
total number of cases. In one case it was present at the time of diagnosis. In 
other case, it was found 8 months after initial diagnosis. 
 Pagliuca and co-workers described a variant called MDS with fibrosis. In 
this case study, we had one case of MDS with fibrosis((1 out of 17)-5%). The 
patient presented with pancytopenia. The marrow showed low cellularity with 
fibrosis. The case was finally diagnosed as MDS with transformation into AML 
by flow cytometry. 
              According to Crail et al disseminated tuberculosis and histoplasmosis 
are the two important infectious diseases resulting in secondary myelofibrosis. 
               According to Kiely et al
 
and Kiang et al metastatic deposits from 
stomach,breast and prostate commonly results in secondary myelofibrosis.  
             In this case study we had one case of CLL with fibrosis, 0ne(1) case of 
TB with fibrosis, two(2) cases of lymphoma with fibrosis and two(2) cases of 
metastatic carcinomatous deposit with fibrosis. 
             Three(3) cases of Acute myeloblastic Leukemia showed fibrosis in bone 
marrow trephine biopsy. 
             One(1) case developed secondary myelofibrosis after radiotherapy.  She 
had a initial diagnosis of Squamous cell carcinoma tonsil and presented with 
secondary myelofibrosis one year after  radiotherapy.  
             The results of this study were comparable to studies done by others. 
SPLENOMEGALY 
                Splenomegaly is a constant and important feature of        
myelofibrosis (IMF). According  to Visani et al  99% of patients with IMF had 
splenomegaly.According to Varki et al and Silverstein et al 90% of patients had 
splenomegaly. In this study (7 out of 8) 87.5% of patients had splenomegaly.  
Among these patients, one underwent splenectomy due to complicating 
symptoms of splenomegaly. Histopathological examination of splenectomy 
specimen revealed extramedullary hematopoiesis. 
            Increase in the spleen size is irrespective of degree of fibrosis.Some of 
the patient with mild degree of fibrosis had more splenomegaly and some 
patients with high degree of reticulin fibrosis had mild splenomegaly.This 
reflects the fact that splenomegaly does not depends upon the degree of reticulin 
fibrosis. This is comparable to study results given by BC Wolf and RS Nieman. 
 
BONE MARROW CELLULARITY AND FIBROSIS 
   In Wolf and Nieman series of case study bone marrow sections revealed a 
wide range of morphological changes. The degree of stromal proliferation was 
extremely variable. Some biopsies out of 35 patients in his study showed 100% 
cellularity.The myeloid,erythroid and megakaryocytes series were all increased. 
  The cellular biopsies showed only slight increase in reticulin fibrosis. 
Majority of the cases,showed only reticulin fibrosis with two cases out of 35 
patients showing collagenous fibrosis.  
         In Wolf and Nieman case study they have observed three constant findings 
in cases of IMF. They are patchy stromal fibrosis,increased number of 
megakaryocytes with megakaryocyte clustering. The megakaryocyte clustering 
appeared to be most numerous in areas of extensive fibrosis.Third feature was 
the distended sinusoids with frequent intrasinusoidal hematopoiesis. 
             In this study out of 25 cases 8 cases showed features of primary 
myelofibrosis. Among 8 cases, all the cases showed stromal proliferation and 
reticulin fibrosis.Stromal proliferation and reticulin fibrosis were patchy in the 
hypercellular marrow and diffuse in case of hypocellular marrow.Hence it can 
be considered that increase in reticulin fibrosis is associated with decrease in the 
bone marrow cellularity. This is similar to results given by Wolf and Nieman. 
 In this study also megakaryocytic proliferation and megakaryocytic 
clustering were more conspicuous in cases of prefibrotic myelofibrosis. Out of 8 
cases, 3 cases showed megakaryocytic clustering and 5 cases showed dysplastic 
megakaryocytes. Intrasinusoidal hematopoiesis was observed in 2 cases. All the 
3 cases which showed megakaryocytic clustering were the cases of  prefibrotic 
myelofibrosis. 
  According to Wolf and Nieman,intrasinusoidal hematopoiesis was 
apparent in the hypocellular marrows. But in this study intrasinusoidal 
hematopoiesis was readily observed in cellular marrows with accompanying 
fibrosis. 
 
BONE MARROW MORPHOMETRY AND MEAN VASCULAR 
DENSITY 
  According to Mesa et al 2000
(38)
 and panteli et al 2005
(39)
 angiogenesis is 
more evident in Primary myelofibrosis. In their study patients with PMF were 
found to have significantly higher values of MVD than those with other 
disorders. In this study also there is a substantial increase in the mean vascular 
density in case of IMF when compared to other cases. Although only some 
cases (3 out of 8 cases)  showed intense increase in the mean vascular density. 
This may be due to decrease in the bone marrow cellularity with accompanying 
increase in the reticulin fibrosis. 
  According to Mesa et al 2000
(38)
 there is increase in marrow  
angiogenesis, with increase in bone marrow cellularity and megakaryocyte 
clustering and were independent of reticulin fibrosis. There is a inverse 
relationship between bone marrow cellularity and fibrosis. 
 In this study, 5 patients had hypercellular marrow.Among 5 patients, 3 
patients had substantial increase in the mean vascular density. Other two 
patients had MVD which were comparable to normal controls. The cases with 
hypocellular marrow does not show significant increase in marrow mean 
vascular density. 
  According to this study,all the patients who had increase in the mean 
vascular  density also had increased spleen size. Hence it may be considered 
that vascular proliferation may be a mother event in causing splenomegaly and 
disease progression. 
 However some patients had increase in the spleen size without increase in 
the Mean vascular density. In such cases, increase in spleen size may be 
attributed to the increased disease duration.   
 
 
 
 
 
 
 
 
 
 
  
SUMMARY 
   The study included total of 25 cases. Among 25 cases,17 cases were 
cases of  secondary myelofibrosis.  
 Most of the cases of secondary myelofibrosis were hematological 
malignancies including leukemia and lymphoma. 
 Disseminated tuberculosis was the most common infectious disorder 
resulting in  secondary myelofibrosis. 
 Primary myelofibrosis constitutes for 38% of total cases. 
 IMF was mostly diagnosed in 5th  decade and 6th  decade with mean age 
of 54 years  in this study.  
 All the patients of IMF presented with Anaemia and 
thrombocytopenia.75% of cases presented with pancytopenia. 
 Megakaryocyte clustering and dysplastic megakaryocytes were more 
conspicuous  in prefibrotic stage of myelofibrosis. 
 Almost all the cases of primary myelofibrosis showed  anisocytosis and 
tear drop cells. 
 Most common type of anaemia in IMF is normocytic normochromic. 
 Most of the cases of IMF had moderate to severe splenomegaly. 
 Increase in bone marrow cellularity was associated with increase in 
MVD. 
 Increase in fibrosis is associated with decrease in cellularity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               CONCLUSION 
  Idiopathic myelofibrosis is a rare myeloproliferative disorder 
characterised by increase in cellularity, bone marrow reticulin fibrosis and 
increased megakaryocytic clustering. Although reticulin fibrosis is a 
characteristic feature of Idiopathic myelofibrosis, it may be less conspicuous in 
early prefibrotic stage.  
  Idiopathic myelofibrosis is usually associated with increase in mean 
vascular density. Increase in mean vascular density,megakaryocytic clustering 
and intrasinusoidal haematopoiesis are considered to be the pre-existing events 
leading to  reticulin fibrosis and splenomegaly. 
 Hence studying the Mean vessel density by using markers such as  
CD34,CD31 and Factor VIII and correlating MVD with fibrosis, splenomegaly 
may be helpful in evaluating the disease progression and patients survival.  
 
 
 
 
 
 
 
                                    ANNEXURE 1 
                                      PROFORMA 
COIMBATORE MEDICAL COLLEGE  
DEPARTMENT OF PATHOLOGY 
COIMBATORE 
Particulars of the patient: 
Name:                                     Hospital: 
Case no:                     Date: 
Age/sex:                                  I.P No: 
Address:                                 Ward no: 
Occupation:                   Religion: 
Presenting complaints and duration: 
Weakness/Dyspnoea/Palpitation/Guiddiness/Angina+/- 
Fever/Sweats/ Abdominal pain/Infection+/- 
Purpura/Ecchymosis/Bleeding diathesis/Skin infections/Parasthesia+/- 
Past history: 
Previous history of anemia 
Transfusions +/-,drugs +/-,liver diseases +/-,chronic diseases, 
Exposure to radiation +/-,chemicals +/-. 
Family history: 
Anemia +/-,bleeding diathesis +/-,malignancy +/-,recurrent jaundice +/-, 
Personal history: 
Diet: appetite: bowel / bladder habits: 
Sleep:alcohol intake : smoking 
 Menstrual history: 
General physical examination: 
Built:  nourishment: conscious: weight 
Pulse :RR :BP:  febrile/afebrile: 
Pallor: jaundice:cynaosis: clubbing: 
Lymphadenophy: edema: mouth: skin: 
Systemic examination: 
P/A: hepatomegaly: splenomegaly: ascites: 
CVS:RS:CNS: musculo-skeletal-bone pains +/-: 
Clinical diagnosis: 
Investigations: 
1.Complete haemogram(autoanalyser) 
SI.no Tests  Observed value 
i.        Hb% 
ii.      RBC count 
iii.      WBC count 
iv.      Platelet count 
v.        PCV 
vi.        MCV 
vii.        MCH 
viii.        MCHC 
ix.      Retic count. 
 
 
 
 
 2.Peripheral smear: 
RBC: 
WBC: 
Platelets: 
Parasites: 
Impression: 
3.Bone marrow study(Bone Marrow Aspiration no) 
Aspirate: 
Cellularity: 
Myeloid:eythroid rartio: 
Erythropoiesis: 
Leucopoiesis 
Megakaryopoiesis: 
4.Bone marrow trephine(HPE NO) 
Cellularity: 
Architecture: 
Presence of fibrosis: 
Focal lesions: 
5.Reticulin stain: 
Grading of fibrosis 
6.Spleen Size: 
7.Mean Vascular Density: 
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                                    ANNEXURE 1 
                                      PROFORMA 
COIMBATORE MEDICAL COLLEGE  
DEPARTMENT OF PATHOLOGY 
COIMBATORE 
Particulars of the patient: 
Name:                                     Hospital: 
Case no:                     Date: 
Age/sex:                                  I.P No: 
Address:                                 Ward no: 
Occupation:                   Religion: 
Presenting complaints and duration: 
Weakness/Dyspnoea/Palpitation/Guiddiness/Angina+/- 
Fever/Sweats/ Abdominal pain/Infection+/- 
Purpura/Ecchymosis/Bleeding diathesis/Skin infections/Parasthesia+/- 
Past history: 
Previous history of anemia 
Transfusions +/-,drugs +/-,liver diseases +/-,chronic diseases, 
Exposure to radiation +/-,chemicals +/-. 
Family history: 
Anemia +/-,bleeding diathesis +/-,malignancy +/-,recurrent jaundice +/-, 
Personal history: 
Diet: appetite: bowel / bladder habits: 
Sleep:alcohol intake : smoking 
 Menstrual history: 
General physical examination: 
Built:  nourishment: conscious: weight 
Pulse :RR :BP:  febrile/afebrile: 
Pallor: jaundice:cynaosis: clubbing: 
Lymphadenophy: edema: mouth: skin: 
Systemic examination: 
P/A: hepatomegaly: splenomegaly: ascites: 
CVS:RS:CNS: musculo-skeletal-bone pains +/-: 
Clinical diagnosis: 
Investigations: 
1.Complete haemogram(autoanalyser) 
SI.no Tests  Observed value 
i.        Hb% 
ii.      RBC count 
iii.      WBC count 
iv.      Platelet count 
v.        PCV 
vi.        MCV 
vii.        MCH 
viii.        MCHC 
ix.      Retic count. 
 
 
 
 
 2.Peripheral smear: 
RBC: 
WBC: 
Platelets: 
Parasites: 
Impression: 
3.Bone marrow study(Bone Marrow Aspiration no) 
Aspirate: 
Cellularity: 
Myeloid:eythroid rartio: 
Erythropoiesis: 
Leucopoiesis 
Megakaryopoiesis: 
4.Bone marrow trephine(HPE NO) 
Cellularity: 
Architecture: 
Presence of fibrosis: 
Focal lesions: 
5.Reticulin stain: 
Grading of fibrosis 
6.Spleen Size: 
7.Mean Vascular Density: 
 
                                                MASTER CHART
 
 
 
 
 
 
 
 
 
 
 
 
S. 
No 
HPE.No
Age / 
Sex
HPE Diagnosis 
Reticulin 
Fibrosis 
(Grade)  
Category 
WBC 
Count* 
/cu.mm
Platelet 
Count*/ 
cu.mm  
Hb 
(gm%) 
Anisopoikilocytosis 
Tear 
Drop 
Cells 
Giant 
Platelet
Bone 
Marrow 
Cellularity
Abnormal 
megakaryocytes 
Meg.cluster
Intrasinusoidal 
hematopoiesis
Presenting 
feature
Splenomegaly
Lymph 
Node 
1 367/11 17/M Primary Myelofibrosis II Primary 2900 34000 5.1 Present Present Present Increased Present Present Present Abd.pain Present        -
2 1972/11 72/M Primary Myelofibrosis II Primary 3800 59000 6.0 Present Present Present Increased Present Present Present pallor Present         -
3 2369/11 56/M Primary Myelofibrosis III Primary 3500 87000 4.2 Present Present - Increased Present Present - pallor Present         -
4 9503/11 52/F Primary Myelofibrosis II Primary 6900 95000 8.0 Present - - Increased Present - - pallor Present         -
5 1395/11 65/M Primary Myelofibrosis III Primary 2400 67000 6.8 Present Present - Increased - - - pallor Present         - 
6 2654/11 58/F Primary Myelofibrosis II Primary 3700 69000 7.3 Present Present - Increased Present - - Fatiguability Present         -
7 1475/11 51/M Primary Myelofibrosis III Primary 1800 47000 4.9 Present Present - Decreased - - - No symptom Present         -
8 4914/11 33/F SLE II Secondary 8650 190000 9.0 - - - Normal - - - -             -         -   
9 2491/11 65/M Lymphoma (NHL) I Secondary 7300 220000 9.2 - - - Increased - - - -             - Enlarged
10 1401/11 55/F SCC TONSIL III Secondary 3800 73000 6.3 - - - Decreased - - - -             -         -
11 2303/11 40/F AML I Secondary 83000 68500 8.2 - - - Increased - - - -             -         -
12 41/12 48/M NHL II Secondary 8400 370000 11.2 - - - Increased - - - -             -         -
13 875/11 75/F AML I Secondary 120000 76000 10.6 - - - Increased - - - -             -         -
14 5176/11 50/F NHL I Secondary 6300 120000 11.0 - - - Increased - - - -             - Enlarged
15 4021/11 15/M Tuberculous Granuloma I Secondary 7900 340000 10.8 - - - Normal - - - -             -         -
16 255/11 77/F CLL II Secondary 63000 280000 11.0 - - - Increased - - - -             -         -
17 8695/11 70/M Multiple Myeloma I Secondary 8600 220000 9.4 - - - Increased - - - -             -         -
18 5526/11 42/M Granulomatous Lesion II Secondary 9200 170000 10.7 - - - Decreased - - - -             -         -
19 3514/12 44/F Metastatic Carcinoma Deposit I Secondary 8900 240000 6.0 - - - Normal - - - -             -         -
20 3098/12 42/F Metastatic Carcinoma Deposit I Secondary 6800 345000 8.4 - - - Normal - - - -             -         -
21 2495/11 60/M Primary Myelofibrosis I Primary 4400 74000 8.7 - - - Decreased - - - pallor        Present         -
22 1760/11 60/M AML II Secondary 96000 110000 9.8 - - - Increased - - - -             -         -
23 2110/11 33/F CML I Secondary 140000 80000 10.9 - - - Increased - - - - Present         -
24 886/11 54/F MDS I Secondary 3600 83000 8.0 Present - - Increased - - - -             -         -
25 3302/11 46/M CML I Secondary 160000 65000 8.5 - - - Increased - - - - Present         -
                                  KEY TO MASTER CHART 
 
         WBC – White blood cells. 
          Hb -  Hemoglobin. 
          NHL – Non hodgkins lymphoma. 
         SLE – Systemic lupus erythematosis. 
         SCC – Squamous cell carcinoma. 
         AML – Acute myeloblastic leukemia. 
         CLL – Chronic lymphocytic leukemia. 
         MDS – Myelodysplastic syndrome. 
 
A CORRELATIVE STUDY ON BONE MARROW ANGIOGENESIS 
WITH BONE MARROW FIBROSIS AND SPLENOMEGALY  
               
ABSTRACT 
 Myelofibrosis is defined as the pathological process characterised by 
increased deposition of collagen type I and type III.Marrow fibrosis usually 
results from the stimulation  of fibroblast by its growth factors.Fibroplasia is 
associated with increased blood flow through the marrow 
substance.Examination of well prepared smears often yields many important 
informations.The initial primitive hematopoiesis gives rise only to erythroid 
precursors and macrophages.Fibrosis is not unique to Primary idiopathic 
myelofibrosis.It occurs in wide variety of diseases including Acute 
leukemias,Myelomas,Lymphomas and Metastatic deposits especially from 
breast and prostate.Idiopathic myelofibrosis is characterised by increase in bone 
marrow reticulin fibrosis and proliferation of blood vessels(Neoangiogenesis – 
Mean vessel density).The study included total of 25 cases of which eight were 
cases of primary myelofibrosis.Most of the cases of secondary myelofibrosis 
were cases of leukemias and lymphomas.IMF was mostly diagnosed in fifth to 
sixth decade. About 75% of  the cases presented with pancytopenia.Increase in 
marrow cellularity is associated with increase in MVD.Increase in fibrosis is 
associated with decrease in cellularity.Increase in the spleen 
size(Extramedullary hematopoiesis) is independent of all the factors.Vascular 
proliferation is considered to be a mother event in causing splenomegaly and 
disease progression. 
KEY WORDS 
  Myelofibrosis,Fibroplasia,Bonemarrow,Reticulinfibrosis,Meanvessel 
density,Splenomegaly.  
